Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2022 | Neoadjuvant chemotherapy in patients with high-grade upper tract urothelial carcinoma

Wesley Yip • 18 Feb 2022
GU Cancers 2022
Bladder Cancer Genitourinary Cancer Cisplatin Gemcitabine

Wesley Yip, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the findings of a multicenter Phase II study evaluating gemcitabine and cisplatin as neoadjuvant chemotherapy in patients with high-grade upper tract urothelial carcinoma (UTUC). Neoadjuvant chemotherapy for high-risk UTUC demonstrates outcomes of favorable pathologic response, is well tolerated requiring minimal delay to surgery without significant perioperative complication risk, and thus should be considered a new standard of care option for patients with high-risk UTUC. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.

More from Wesley Yip

The importance of UC tumor characterization for personalized medicine
0:43
The importance of UC tumor characterization for personalized medicine
Wesley Yip • 18 Feb 2022
Upper tract UC transcriptome profiling and immune microenvironment characterization
1:55
Upper tract UC transcriptome profiling and immune microenvironment characterization
Wesley Yip • 18 Feb 2022
The effect of remote learning on clinical practice for urothelial carcinoma (UC)
1:34
The effect of remote learning on clinical practice for urothelial carcinoma (UC)
Wesley Yip • 18 Feb 2022

Related Videos

Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
1:55
Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
Sarah Howlett • 26 Oct 2026
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
2:20
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
Jens Bedke • 26 Oct 2026
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
2:24
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
Jens Bedke • 26 Oct 2026
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
2:58
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
Jens Bedke • 26 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals